What's on the Horizon for the Targeted Treatment of Type 2-low Asthma?

Chest. 2023 Jun;163(6):1362-1364. doi: 10.1016/j.chest.2022.12.017.

Authors

Xianglan Yao¹, Amisha V Barochia¹, Stewart J Levine²

Affiliations

¹ Laboratory of Asthma and Lung Inflammation, Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
² Laboratory of Asthma and Lung Inflammation, Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address: levines@nhlbi.nih.gov.

PMID: 37295879
DOI: 10.1016/j.chest.2022.12.017

No abstract available

Keywords: IL-33; IL-6; mast cell; thymic stromal lymphopoietin; type 2-low asthma.

Publication types

Editorial

MeSH terms

Asthma* / drug therapy
Cytokines
Humans

Substances

Cytokines